The American College of Chest Physicians (CHEST) is hosting its annual meeting, CHEST 2024. It will take place from October 6 – 9 in the vibrant city of Boston, Massachusetts. This prestigious event will bring together leading experts in the field of chest medicine, offering attendees an unparalleled educational experience and valuable networking opportunities aimed at enhancing patient care.

To ensure your participation in this exceptional event, we urge you to register promptly by clicking this link. By doing so, you will be able to secure accommodations, access travel details, plan your itinerary, and secure your spot for educational and networking functions before they reach full capacity.

Highlighted in the program are several key sessions at CHEST 2024 focusing on asthma, including discussions on the latest guidelines for biologics in severe asthma and a comparative analysis of GINA and EPR-4 asthma guidelines. We are eager to delve into these sessions, as well as the other engaging topics on the agenda. The sessions have been thoughtfully arranged in chronological order for your convenience.

Advances in Non-T2 Asthma

  • Date/Time: 10/6/24 @ 2:45 PM
  • Location: Convention Center 253 B
  • Description: Asthma is a complex disorder with various phenotypes and endotypes, each characterized by specific inflammatory patterns related to its underlying pathophysiology. In this engaging session, the speakers will present an overview of the epidemiology and immune profiles of non-T2 asthma, followed by a discussion on approved therapies and potential areas for future research.

Should We Be Targeting Eosinophils Regardless of Allergic Status in Patients With Severe Eosinophilic Asthma?

  • Date/Time: 10/7/24 @ 12:15 PM
  • Location: Convention Center Exhibit Hall: Learning Theater 4
  • Description: Dr. Alexis Smith will challenge your understanding of the strengths and limitations of specific biomarkers in managing severe asthma. She will delve into the significance of eosinophils as a catalyst for severe asthma and examine the role of eosinophilic inflammation in both allergic and non-allergic asthma. The program will also encompass crucial clinical trial data and the most recent real-world evidence supporting the treatment of severe eosinophilic asthma with NUCALA.

 Asthma and COPD Section: Inequity in Access and Adherence to Biologics in Severe Asthma

  • Date/Time: 10/7/24 @ 1:00 PM
  • Location: Convention Center Exhibit Hall: Experience CHEST
  • Description: Biologic therapies have transformed the landscape of treatment options for adult patients suffering from poorly controlled, severe, persistent asthma. These cutting-edge treatments have emerged as a crucial component in managing asthma while minimizing the use of steroids. However, despite their effectiveness, access to biologic medications remains a significant challenge. This session will delve into the social determinants that impact access and adherence to biologic treatments, including patient demographics and insurance-related barriers. The discussion will also explore potential strategies to address and overcome these limitations in accessing biologic medications.

Comparison of GINA and EPR-4 Asthma Guidelines: Differences and Challenges—Literature Review

  • Date/Time: 10/8/24 @  8:00 AM
  • Location: Convention Center 210 B
  • Description: During this session, the variations and distinctions between two guidelines will be discussed. The presenters will delve into the methodology behind the differing recommendations derived from the same dataset and discuss strategies for harmonizing these disparities to enhance patient care.

Asthma and COPD Section: Pulmonologist Primer for Smoking-Related Small Airway and Interstitial Lung Diseases

  • Date/Time: 10/8/24 @ 2:00 PM 
  • Location: Convention Center Exhibit Hall: Experience CHEST
  • Description: Smoking tobacco is linked to various types of small airway and interstitial lung diseases (ILD), presenting a diverse range of disorders that can be challenging to diagnose and often require a multidisciplinary approach. Conditions such as chronic bronchitis, emphysema, desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), Langerhans cell histiocytosis (LCH), and acute eosinophilic pneumonia (AEP) primarily affect the small airways and lung parenchyma. On the other hand, idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE), and nonspecific interstitial pneumonia (NSIP) may also have smoking tobacco as a potential risk factor, along with genetic predisposition and environmental triggers. Recognizing characteristic radiographic patterns and histopathologic findings is crucial as it can significantly impact the management and prognosis of these conditions.

CHEST Guidelines on Biologics for Severe Asthma: Evidence, Recommendations, and Clinical Implications

  • Date/Time: Tuesday, October 8 4:00 PM – 5:00 PM EDT
  • Location: Convention Center 253 B
  • Description: In 2024, under the guidance of CHEST, the first-ever guideline on selecting biologics for severe asthma will be released. During this session, participants will have the opportunity to hear from the co-chairs, panelists, methodologist, and guideline development experts involved in creating this groundbreaking guideline. They will gain insight into the evidence-based recommendations and expert panel consensus that are outlined within the guideline. The session will feature brief presentations that offer an overview of the guideline development process, the PICO questions that were addressed, and the recommendations that were ultimately made. Following these presentations, there will be a moderated panel discussion where audience members can pose questions.

Insights Into Asthma Plus Entities: Think Outside the Box and Focus on Eosinophilic Lung Diseases

  • Date/Time: 10/9/24 @ 11:15 AM 
  • Location: Convention Center 253 A
  • Description: This session is designed to enhance the knowledge and skills of pulmonary care specialists and primary care physicians in the management of asthma and its related conditions. The emphasis will be on the significance of precise diagnosis and successful treatment approaches for complex asthma cases, as well as the early detection of asthma plus conditions. The speakers will delve into in-depth case studies, with a particular focus on individuals with asthma and eosinophilic lung diseases. These discussions will encompass the diagnostic procedures and treatment protocols involved. The primary objective is to elevate the proficiency of healthcare providers in recognizing and addressing these syndromes, ultimately leading to improved patient outcomes.

Biologics and Maintenance Therapy in Severe Asthma: A Pro-Con Debate

  • Date/Time: Wednesday, October 9 3:30 PM – 4:30 PM EDT
  • Location: Convention Center 206 AB
  • Description: Fixed and open-triple therapy is increasingly accessible for patients suffering from severe and hard-to-treat asthma. Currently, there is a lack of studies pinpointing the ideal candidates who would benefit from using a LAMA as opposed to higher doses of ICS/LABA, or the selection of biologics. The decision to step-up from an ICS/LABA is left to the discretion of treating physicians. This session aims to provide guidance for clinicians facing this common dilemma in their daily practice.

The CHEST Conference 2024 promises to deliver in-depth discussions on the latest advancements in asthma treatment, providing attendees with valuable insights and knowledge that will undoubtedly impact their practice. We look forward to seeing you in what is sure to be an enlightening and captivating conference experience.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2024 Guideline Central, All Rights Reserved.